Impact of hepatitis C triple therapy availability upon the number of patients to be treated and associated costs in France: A model-based analysis

Gut

Volumn 61, Issue 2, 2012, Pages 290-296

  Deuffic Burban, Sylvie ^a,b   Mathurin, Philippe ^a,c   Pol, Stanislas ^d   Larsen, Christine ^e   Roudot Thoraval, Françoise ^f   Desenclos, Jean Claude ^e   Dhumeaux, Daniel ^f   Yazdanpanah, Yazdan ^a,b,g  

^a UNIVERSITÉ DE LILLE   (France)

^b UNIV LILLE   (France)

^c LILLE UNIVERSITY HOSPITAL   (France)

^d Département des Maladies Infectieuses ^*  (France)

^e INSTITUT DE VEILLE SANITAIRE   (France)

^f HENRI MONDOR HOSPITAL   (France)

^g CENTRE HOSPITALIER DE TOURCOING   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BOCEPREVIR; PEGINTERFERON; PROTEINASE INHIBITOR; RIBAVIRIN; TELAPREVIR;

ADULT; AGED; ANTIVIRAL THERAPY; ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; COST BENEFIT ANALYSIS; DISEASE CLASSIFICATION; DRUG COST; EXPERIMENTAL MODEL; FRANCE; HEALTH CARE AVAILABILITY; HEALTH CARE NEED; HEPATITIS C; HUMAN; LIVER FIBROSIS; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; SCREENING TEST; TREATMENT DURATION; TREATMENT RESPONSE; VIRUS LOAD;

ADOLESCENT; ADULT; AGED; ANTIVIRAL AGENTS; COMPUTER SIMULATION; DISEASE PROGRESSION; DRUG COSTS; DRUG THERAPY, COMBINATION; DRUG UTILIZATION; FRANCE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; MARKOV CHAINS; MIDDLE AGED; MODELS, ECONOMIC; POLYETHYLENE GLYCOLS; PROTEASE INHIBITORS; RECOMBINANT PROTEINS; RIBAVIRIN; YOUNG ADULT;

EID: 84855205721     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gutjnl-2011-300586     Document Type: Article

References (36)

1. Asselah T, Marcellin P. New direct-acting antivirals' combination for the treatment of chronic hepatitis C. Liver Int 2011;31(Suppl 1):68-77.
2. Trépo C, Pradat P. Hepatitis C virus infection in Western Europe. J Hepatol 1999;31 (Suppl 1):80-3. (Pubitemid 30002696)
3. Payan C, Roudot-Thoraval F, Marcellin P, et al. Changing of hepatitis C virus genotype patterns in France at the beginning of the third millenium: The GEMHEP GenoCII Study. J Viral Hepat 2005;12:405-13. (Pubitemid 40961481)
4. McHutchison JG, Manns MP, Muir AJ, et al. Telaprevir for previously treated chronic HCV infection. N Engl J Med 2010;362:1292-303.
5. Bacon BR, Gordon SC, Lawitz E, et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011;364:1207-17.
6. Zeuzem S, Andreone P, Pol S, et al. REALIZE trial final results: telaprevir-based regimen for genotype 1 hepatitis C virus infection in patients with prior null response, partial response or relapse to peginterferon/ ribavirin. J Hepatol 2011;54:S3.
7. Hézode C, Forestier N, Dusheiko G, et al. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med 2009;360:1839-50.
8. Jacobson IM, McHutchison JG, Dusheiko GM, et al. Telaprevir in combination with Peginterferon and ribavirin in genotype 1 HCV treatment-naïve patients: final results of phase 3 ADVANCE study. Hepatology 2010;52:427A. Abstract 211.
9. Kwo PY, Lawitz EJ, McCone J, et al. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial. Lancet 2010;376:705-16.
10. McHutchison JG, Everson GT, Gordon SC, et al. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med 2009;360:1827-38.
11. Poordad F, McCone J, Bacon BR, et al. Boceprevir (BOC) combined with peginterferon alfa-2b/ribavirin (P/R) for treatment-naive patients with hepatitis C virus (HCV) genotype (G) 1: SPRINT-2 final results. Hepatology 2010;52:402. A. Abstract LB-4.
12. Sherman KE, Flamm SL, Afdhal NH, et al. Telaprevir in combination with peginterferon alfa3a and ribavirin for 34 or 48 weeks in treatment-naïve genotype 1 HCV patients who achieved an extended rapid viral response: final results of the Phase 3 ILLUMINATE study. Hepatology 2010;52:410A. Abstract LB-2.
13. Deuffic-Burban S, Deltenre P, Louvet A, et al. Impact of viral eradication on mortality related to hepatitis C: a modeling approach in France. J Hepatol 2008;49:175-83.
14. Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, DOSVIRC groups. Lancet 1997;349:825-32. (Pubitemid 27129209)
15. Roudot-Thoraval F, Bastie A, Pawlotsky JM, et al. Epidemiological factors affecting the severity of hepatitis C virus-related liver disease: a French survey of 6,664 patients. The Study Group for the Prevalence and the Epidemiology of Hepatitis C Virus. Hepatology 1997;26:485-90. (Pubitemid 27328330)
16. Martinot-Peignoux M, Roudot-Thoraval F, Mendel I, et al. Hepatitis C virus genotypes in France: relationship with epidemiology, pathogenicity and response to interferon therapy. The GEMHEP. J Viral Hepat 1999;6:435-43.
17. Pagliaro L, Peri V, Linea C, et al. Natural history of chronic hepatitis C. Ital J Gastroenterol Hepatol 1999;31:28-44. (Pubitemid 29103445)
18. Poynard T, Ratziu V, Charlotte F, et al. Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis C. J Hepatol 2001;34:730-9. (Pubitemid 32488789)
19. Serfaty L, Aumaitre H, Chazouilleres O, et al. Determinants of outcome of compensated hepatitis C virus-related cirrhosis. Hepatology 1998;27:1435-40. (Pubitemid 28227875)
20. Corrao G, Arico S. Independent and combined action of hepatitis C virus infection and alcohol consumption on the risk of symptomatic liver cirrhosis. Hepatology 1998;27:914-19. (Pubitemid 28160474)
21. Degos F, Christidis C, Ganne-Carrie N, et al. Hepatitis C virus related cirrhosis: time to occurrence of hepatocellular carcinoma and death. Gut 2000;47:131-6. (Pubitemid 30430422)
22. D'Amico G, Garcia-Tsao G, Pagliaro L. Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. J Hepatol 2006;44:217-31. (Pubitemid 41772537)
23. El-Serag HB, Mason AC, Key C. Trends in survival of patients with hepatocellular carcinoma between 1977 and 1996 in the United States. Hepatology 2001;33:62-5. (Pubitemid 32016888)
24. El-Serag HB. Hepatocellular carcinoma: recent trends in the United States. Gastroenterology 2004;127(5 Suppl 1):S27-34. (Pubitemid 39423367)
25. Dubois F, Desenclos JC, Mariotte N, et al. Hepatitis C in a French population-based survey, 1994: Seroprevalence, frequency of viremia, genotype distribution, and risk factors. The Collaborative Study Group. Hepatology 1997;25:1490-6. (Pubitemid 27250774)
26. Meffre C, Le Strat Y, Delarocque-Astagneau E, et al. Prevalence of hepatitis B and hepatitis C virus infections in France in 2004: social factors are important predictors after adjusting for known risk factors. J Med Virol 2010;82:546-55.
27. Bourliere M, Ouzan D, Rosenheim M, et al. Efficacy of peginterferon alpha-2a and ribavirin in 2101 patients with HCV infection in real-life clinical practice: results of the French HEPATYS study. Hepatology 2007;46:366A.
28. Pariente A, Lahmek P, Duprat C, et al. Treatment of chronic hepatitis C with pegylated interferon and ribavirin in treatment-naive patients in 'true life': a plea in favor of independent postmarketing evaluations. Eur J Gastroenterol Hepatol 2010;22:1297-302.
29. Delarocque-Astagneau E, Meffre C, Dubois F, et al. The impact of the prevention programme of hepatitis C over more than a decade: the French experience. J Viral Hepat 2010;17:435-43.
30. Marcellin P, Pequignot F, Delarocque-Astagneau E, et al. Mortality related to chronic hepatitis B and chronic hepatitis C in France: evidence for the role of HIV coinfection and alcohol consumption. J Hepatol 2008;48:200-7.
31. Association Française pour l'Etude du Foie (AFEF). Prise de position de l'Association Française pour l'Etude du Foie (AFEF) sur les trithérapies (Peg-IFN + ribavirine + inhibiteur de protéase) dans la prise en charge des malades atteints d'hépatite chronique CAvril. 2011. http://www.afef.asso.fr/rc/org/afef/htm/Article/2011/htm-20110414-094626- 465/src/htm-fullText/fr/POSITION-AFEF-TRITHERAPIE-VHC.pdf.
32. Thompson AJ, Muir AJ, Sulkowski MS, et al. Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. Gastroenterology 2010;139:120-9.e18.
33. Jacobson IM, McHutchison JG, Dusheiko G, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011;364:2405-16.
34. Poordad F, McCone J Jr, Bacon BR, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011;364:1195-206.
35. Lettmeier B, Mühlberger N, Schwarzer R, et al. Market uptake of new antiviral drugs for the treatment of hepatitis C. J Hepatol 2008;49:528-36.
36. Deuffic-Burban S, Deltenre P, Buti M, et al. HCV burden in Europe: impact of national treatment practices on future HCV-related morbidity and mortality through a modeling approach. J Hepatol 2011;54:S54.